Follicular lymphoma: are there proteomics tests I should consider to guide my care

TL;DR: Proteomics tests (protein analysis) can help guide treatment for follicular lymphoma by identifying which drugs your tumor is likely to respond to, but these tests are still emerging and not yet standard care—talk to your oncologist about whether one makes sense for your specific situation.

KEY POINTS:

• Proteomics tests measure protein levels in your tumor tissue to predict which treatments will work best for you personally
• These tests can identify targets for antibody-drug conjugates (ADCs) and other targeted therapies that may be options for follicular lymphoma
• Protein biomarkers like PD-L1 and others can help your doctor choose between standard treatments or identify clinical trials you might qualify for
• This technology is advancing rapidly but isn't yet routine standard-of-care for most follicular lymphoma patients
• Your oncologist can help determine if proteomics testing would change your treatment plan before ordering it

NEXT STEP: Ask your oncologist: "Would a proteomics test help guide my treatment decisions, or are there other biomarker tests you'd recommend for my follicular lymphoma?"

---

FULL ANSWER

What Are Proteomics Tests?

Proteomics testing measures the protein levels in your tumor tissue. Think of it this way: your DNA (genes) is like a recipe book, but proteins are the actual ingredients and finished dishes. Just because a gene exists doesn't mean the protein it makes is actually present in high amounts in your cancer cells. Proteomics tests directly measure what proteins are actually being made and expressed in your tumor—which is what your cancer drugs actually target.

According to research presented by proteomics expert Sheeno Thyparambil, "All your drugs are actually acting against proteins, so the question becomes: should I measure the levels of protein to see what's actually expressed?" This is the core logic behind proteomics testing for cancer treatment guidance.

How Proteomics Tests Work for Cancer Treatment

The most common proteomics approach uses mass spectrometry, a laboratory technique that identifies and measures specific proteins in tumor tissue. Here's the practical process:

1. Sample collection: Your oncologist obtains tumor tissue (usually from a biopsy or archived tissue from previous procedures)
2. Protein analysis: The lab measures levels of 50-100+ biomarkers (protein targets) relevant to cancer treatment
3. Clinical report: Within days, your doctor receives a report showing which proteins are highly expressed in your tumor
4. Treatment guidance: The report suggests which drugs, drug combinations, or clinical trials might be best matches for your tumor's protein profile

According to the CancerPatientLab webinar on proteomics, "Once the lab receives two slides of tumor tissue (FFPE—formalin-fixed paraffin-embedded), five days later a clinical report goes to the oncologist with the levels of 72 biomarkers."

Proteomics for Follicular Lymphoma: What's Relevant?

While most proteomics research has focused on solid tumors (breast, prostate, gastric cancers), the principles apply to lymphomas as well. For follicular lymphoma specifically, proteomics could identify:

Protein biomarkers that guide treatment decisions:

• PD-L1 (programmed death ligand-1): A protein that helps cancer cells hide from the immune system. High PD-L1 expression may indicate benefit from checkpoint inhibitor immunotherapies
• CD20: The standard target for rituximab and other monoclonal antibodies used in follicular lymphoma treatment
• Other emerging targets: Proteins that might make your lymphoma vulnerable to antibody-drug conjugates (ADCs) or other targeted therapies

How this helps your care:

• If your tumor has high expression of certain proteins, your oncologist might recommend specific drugs or clinical trials targeting those proteins
• If your tumor lacks certain protein targets, your doctor might avoid drugs unlikely to work and preserve them for future use
• Proteomics can help identify which chemotherapy drugs your tumor is likely to respond to (or resist)

Current Evidence and Limitations for Lymphomas

Important context: Most proteomics testing development has focused on solid tumors. According to the NCCN Guidelines for lymphomas, biomarker-directed treatment is less standardized than in other cancers. However, the principles are sound:

• Proteomics can identify actionable protein targets
• Results can steer treatment toward clinical trials matching your tumor's protein profile
• The technology is advancing rapidly, with new biomarkers being discovered regularly

What we don't yet have: Specific, large clinical trials proving that proteomics-guided treatment improves outcomes specifically in follicular lymphoma. This is an area of active research.

Questions to Ask Your Oncologist

Before pursuing proteomics testing, discuss these questions with your lymphoma specialist:

1. "Would a proteomics test change my treatment plan right now, or would it just confirm what we're already planning?" (Testing should only be done if results might change management)

2. "Are there specific protein targets in follicular lymphoma that you're looking for that would guide my next treatment?"

3. "Are there clinical trials I might qualify for based on protein biomarkers in my tumor?"

4. "What's the cost, and would my insurance cover it?" (Proteomics testing can be expensive and coverage varies)

5. "If I do get tested, how quickly would results come back, and how would you use them?"

6. "Are there other biomarker tests (like gene expression profiling or genomic testing) that might be more established for my type of lymphoma?"

Alternative/Complementary Testing

Your oncologist might also consider:

• Genomic testing (DNA-based): Identifies genetic mutations that might predict treatment response
• Gene expression profiling: Measures which genes are "turned on" in your tumor
• Flow cytometry: Standard test for lymphomas that identifies cell surface markers
• Functional testing: Some labs test how your tumor cells respond to drugs in a test tube

The Bottom Line

Proteomics testing is a promising tool that can help personalize follicular lymphoma treatment by identifying protein targets and predicting drug response. However:

✅ Consider it if:

• You're at a decision point where multiple treatment options exist
• Your oncologist thinks specific protein biomarkers would change your treatment choice
• You're interested in clinical trials and want to know what protein targets your tumor has
• You've had previous treatments fail and need new strategies

⚠️ Be cautious if:

• Your treatment plan is already clear and standard
• The test is expensive and unlikely to change management
• You're early in treatment with well-established standard options

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.